Suggested strategies for the long-term treatment
| Patient . | Strategy . |
|---|---|
| All patients with SVT | At least 3 mo of anticoagulant treatment |
| Patients with SVT secondary to surgery | Treatment discontinuation after 3-6 mo |
| Patients with PVT, MVT secondary to nonsurgical transient risk factors (eg, hormonal therapy, abdominal infections) | Treatment discontinuation after 6-12 mo |
| Patients with PVT, MVT secondary to permanent risk factors (eg, cirrhosis, chronic inflammatory disorders, cancer, MPNs, autoimmune disorders, major thrombophilia*) | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
| Patients with unprovoked SVT | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
| Patients with BCS | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
| Patient . | Strategy . |
|---|---|
| All patients with SVT | At least 3 mo of anticoagulant treatment |
| Patients with SVT secondary to surgery | Treatment discontinuation after 3-6 mo |
| Patients with PVT, MVT secondary to nonsurgical transient risk factors (eg, hormonal therapy, abdominal infections) | Treatment discontinuation after 6-12 mo |
| Patients with PVT, MVT secondary to permanent risk factors (eg, cirrhosis, chronic inflammatory disorders, cancer, MPNs, autoimmune disorders, major thrombophilia*) | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
| Patients with unprovoked SVT | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
| Patients with BCS | Indefinite anticoagulant treatment with periodic reassessment of bleeding profile |
Antiphospholipid antibodies, double heterozygosity for Factor V Leiden mutation and G20210A mutation in prothrombin gene or single homozygosity.